Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials

Expert Rev Cardiovasc Ther. 2010 Sep;8(9):1207-10. doi: 10.1586/erc.10.96.
No abstract available

Publication types

  • Comparative Study
  • Editorial

MeSH terms

  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / adverse effects
  • Coronary Artery Disease / physiopathology
  • Coronary Artery Disease / therapy*
  • Drug-Eluting Stents*
  • Everolimus
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / adverse effects
  • Paclitaxel / administration & dosage
  • Paclitaxel / adverse effects
  • Randomized Controlled Trials as Topic
  • Sirolimus / administration & dosage
  • Sirolimus / adverse effects
  • Sirolimus / analogs & derivatives*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Phytogenic
  • Immunosuppressive Agents
  • Everolimus
  • Paclitaxel
  • Sirolimus